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Aims: To review the major trials that evaluated the efficacy and safety of the use of sibutramine 
for weight loss and the impact of this agent on obesity-related disorders.
Methods and results: The most important articles on sibutramine up to January 2009 were 
located by a PubMed and Medline search. Sibutramine reduces food intake and body weight 
more than placebo and has positive effects on the lipid profile (mainly triglycerides and high 
density lipoprotein cholesterol), glycemic control and inflammatory markers in studies for 
up to one year. Preliminary studies showed that sibutramine may also improve other obesity-
associated disorders such as polycystic ovary syndrome, left ventricular hypertrophy, binge 
eating disorder and adolescent obesity. The high discontinuation rates and some safety issues 
mainly due to the increase in blood pressure and pulse rate have to be considered. Additionally, 
it has not yet been established that treatment with sibutramine will reduce cardiovascular events 
and total mortality.
Conclusions: Sibutramine, in conjunction with lifestyle measures, is a useful drug for reducing 
body weight and improving associated cardiometabolic risk factors and obesity-related disorders. 
Studies of longer duration are required to determine the precise indications of the drug, to evaluate 
safety issues and to assess its efficacy on cardiovascular mortality.
Keywords: Sibutramine, obesity, weight loss, cardiometabolic risk factors, obesity-related 
disorders, side-effects
Introduction
The prevalence of obesity is increasing substantially in both developed and developing 
countries during the last decades.1 Almost two thirds of the adult US population is 
overweight and almost one third is obese.2 Similar high rates and trends were reported 
in certain European countries.3 Obesity, particularly when associated with abdominal 
fat distribution, increases the risk for cardiovascular morbidity and mortality.4,5 
Overweight and obesity also increase the risk for cancer-related mortality and for all 
cause mortality6 and result in reduced life expectancy.7,8
Lifestyle measures are the cornerstone of prevention and treatment of obesity.9 
However, adding antiobesity agents can be considered in obese patients who did 
not achieve sufficient weight loss after lifestyle modifications and if patients accept 
risks and benefits of these agents.9,10 Two agents are currently approved for long-
term management of obesity, sibutramine and orlistat. The newer antiobesity drug 
rimonabant, a cannabinoid receptor antagonist, was recently suspended from the 
market due to increased incidents of suicidal behavior and depression among treated 
patients.11Vascular Health and Risk Management 2009:5 442
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Data regarding the efficacy and safety of sibutramine 
were reported in recent reviews.12,13 In the present paper 
we describe the mechanism of action of sibutramine and 
present the most important trials that evaluated the body 
weight-reduction potential of this agent. Furthermore, we 
comment on recent studies evaluating the effects of sibutra-
mine on cardiometabolic risk factors and in specific patho-
logical conditions related with obesity such as polycystic 
ovary syndrome, sleep apnea syndrome, left ventricular 
hypertrophy, binge eating disorder and in adolescent obesity. 
Finally, we evaluated studies comparing sibutramine with 
orlistat and address the safety issues associated with the 
use of this agent. The most important relevant articles on 
sibutramine until January 2009 were reviewed through a 
PubMed and Medline search.
Mechanism of action
Sibutramine induces weight loss by selectively inhibiting the 
neuronal reuptake of serotonin and norepinephrine within 
the hypothalamus.10 To a smaller degree it also inhibits 
the reuptake of dopamine.10 Studies in subjects who were 
not attempting to lose weight showed that sibutramine acts 
by reducing food intake.14,15 This appears to result from an 
increase in satiety and a reduction in appetite.15–19 It was also 
shown that sibutramine might augment energy expenditure 
in both the basal and fed states.16 In addition, sibutramine 
prevented the decrease in energy expenditure and basal 
metabolic rate that follows weight loss.18,20,21 However, 
other studies did not find any change in metabolic rate with 
sibutramine.22 The action on thermogenesis seems of minor 
importance in weight reduction.
Besides increased sympathetic activity, sibutramine 
treatment in animals and in humans may alter central neuro-
peptide Y (NPY), and proopiomelanocortin (POMC) mRNA 
levels and, additionally, the potent anorexigenic hormones 
leptin and insulin.23,24 Concerning the effects on leptin, it was 
reported that sibutramine might maintain or even increase 
leptin transport into the brain during weight loss, while this 
did not occur during orlistat treatment.25
Studies assessing the weight-lowering 
potential of sibutramine
In an early dose-ranging study in 235 overweight or obese 
patients, 10 mg sibutramine per day were as effective as 
15 mg/day; both doses were more effective than the 5 mg/day 
dose.26 In another study in 485 obese men, sibutramine (10 or 
15 mg/day for one year) and behavior treatment reduced 
body weight, body mass index (BMI), waist circumference, 
and waist/hip ratio (WHR) more than behavior therapy and 
placebo.27 Greater proportions of patients in both sibutra-
mine groups lost at least 5% or 10% of their baseline body 
weight compared with the placebo group.27 Both doses were 
more effective than placebo and the 15 mg/day dose was 
more effective than the 10 mg/day dose.27 In a larger dose-
ranging study in 1047 obese patients, sibutramine (1, 5, 10, 
15, 20, or 30 mg/day for 24 weeks) induced dose-dependent 
weight loss, which was significantly higher than placebo.28 
In a meta-analysis, weight loss with sibutramine was larger 
with the 15 mg/day dose.29 The dosage range of sibutramine 
is 5 to 15 mg/day; 10 mg/day as a single daily dose is the 
recommended starting dose.30
In another study in 322 overweight or obese patients, 
sibutramine (20 mg/day for 24 weeks) reduced body weight, 
BMI and waist circumference and improved the quality of life 
more than placebo.31 In a recent study in 362 obese patients, 
sibutramine (15 mg/day for 54 weeks) reduced body weight by 
a mean of 3.0 kg more than placebo.32 The efficacy of sibutra-
mine appears to be similar in every day clinical practice. 
In a nonblinded study in 588 obese patients, sibutramine 
(10–15 mg/day for one year) within a weight management 
program induced greater reductions in body weight, BMI, 
waist circumference and body fat than the weight manage-
ment program alone.33 More patients in the sibutramine group 
experienced 5% weight loss (47.3% vs 19.1% in the weight 
management program only group; p  0.001).33
In a recent meta-analysis of randomized placebo-
controlled trials of sibutramine of at least one year in dura-
tion (10 studies with 2,623 patients), sibutramine reduced 
body weight by 4.2 kg (3.6 to 4.7 kg) more than placebo.34 
A higher proportion of patients treated with sibutramine 
achieved 5% weight loss (55% vs 27% in the placebo 
group) or 10% weight loss (28% vs 10% in the placebo 
group).34 There was also a greater reduction in BMI in the 
sibutramine group. Sibutramine appears to reduce visceral 
more than subcutaneous adiposity. In the meta-analysis by 
Rucker and colleagues34 there was a 4 cm decrease in waist 
circumference with sibutramine. In a subgroup of patients in 
the Sibutramine Trial of Obesity Reduction and Maintenance 
(STORM) study, computed tomography showed a preferen-
tial reduction in visceral fat.35 Similar results were reported in 
a smaller study using magnetic resonance imaging to assess 
changes in adipose tissue.36
Sibutramine also prevents weight regain when administered 
after a dietary intervention. In the STORM study 605 obese 
patients were given sibutramine (10 mg/day) and followed 
a low-energy diet for six months.37 Patients achieving 5% Vascular Health and Risk Management 2009:5 443
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weight loss after six months (n = 467) were randomly 
allocated to continue sibutramine (10 mg/day uptitrated to 
20 mg/day if weight regain occurred; n = 350) or placebo 
(n = 114) for 18 months.37 The sibutramine group had less 
weight regain than the placebo group.37 More patients in 
the sibutramine group maintained 80% of the weight loss 
achieved during the first 6 months of the study (43% vs 16% 
in the placebo group; p  0.001).37 Some studies showed 
that sibutramine can prevent weight regain after short-term 
(1–3 months) very-low-calorie diet.38,39 In these patients, 
treatment with sibutramine for 12–18 months maintained 
weight loss in a higher proportion of patients than placebo.38,39 
In some of these studies, sibutramine induced additional 
weight loss and a reduction in waist circumference.38 A very 
recent review on clinical trials of weight loss maintenance 
revealed that treatment with sibutramine combined with 
lifestyle measures was efficacious in reducing weight regain 
after weight loss.40
It should be mentioned that when sibutramine is combined 
with behavior therapy the resulting weight loss appears to be 
more pronounced. In a study in 53 obese women, combining 
sibutramine (10 to 15 mg/day for one year) with behavior 
therapy or portion-controlled diet induced greater reductions 
in body weight than sibutramine alone.41 In a larger study 
in 224 obese patients, sibutramine (10 to 15 mg/day for one 
year) with behavior therapy resulted in greater weight loss 
than either sibutramine or behavior therapy alone.42 The 
prevalence of metabolic syndrome (MetS) was also reduced 
more in the former group and this was attributed to the greater 
weight loss in this group.43
Interestingly, some studies showed that intermittent treat-
ment with sibutramine might be as effective as continuous 
administration of this agent.44 In 1,001 obese patients, 
continuous treatment with sibutramine (15 mg/day) for 
48 weeks induced similar weight and waist circumference 
reductions with intermittent treatment (sibutramine 15 mg/day 
only during weeks 1–12, 19–30 and 37–48).44 In addition, the 
proportion of patients experiencing a serious adverse event 
was lower in the intermittently treated group.44
It is of interest that weight loss achieved during the first 
month of sibutramine treatment was predictive of long-term 
weight loss.28,41 A meta-analysis of seven sibutramine studies 
(n = 928) showed that a weight loss of 4 kg at three months 
was the most sensitive predictor of achieving 5% weight 
loss at 12 months.45 It was suggested that it might be reason-
able to discontinue sibutramine in patients who do not lose at 
least 5% of their body weight within the first 3–6 months.46 
However, a Swedish study suggested that sibutramine is not 
discontinued in the majority of patients who do not achieve 
this target.47
Other predictors of weight loss during sibutramine 
treatment were also identified in some reports. In the STORM 
study, higher body weight at baseline was the only predictor 
of greater weight loss at six months and weight maintenance 
at 24 months.48 In other studies, higher baseline BMI also 
predicted greater weight loss at 4 and 12 months.19 A younger 
age, lower depression scores, less restrained eating and lower 
energy intake at baseline also appear to predict greater weight 
loss.19,49,50 Preliminary findings suggest that specific genes 
might modulate the response to sibutramine treatment.51–53 
In 149 obese women, the GG and AA genotypes of the 
phenylethanolamine N-methyltransferase gene (the rate-
limiting enzyme in catecholamine biosynthesis) were associ-
ated with greater weight loss with sibutramine than the AG 
genotype.51 Another study in 111 patients reported that the 
GNβ3 CC genotype predicted 5% weight loss with sibutra-
mine.52 Patients with the GNβ3 TC/TT genotypes derived no 
benefit from sibutramine.52 The GNβ3 gene encodes the β3 
subunit of the G-proteins, which are the second messengers 
of the adrenergic and serotoninergic receptors.52,53 In contrast, 
in a more recent study in 181 subjects, the GNβ3 TC/TT 
genotypes were associated with greater weight loss with 
sibutramine treatment.53 The α2A CC and 5HTTLPR LS/SS 
genotypes and the combinations of these 3 genotypes (GNβ3 
TC/TT, α2A CC and 5HTTLPR LS/SS) were also associated 
with greater weight loss.53 The α2A and 5HTTLPR genes 
encode the α2A adrenoreceptor and the serotonin transporter 
protein, respectively.53
Sibutramine and cardiometabolic 
risk factors
Overweight and obesity increase the risk for developing 
type 2 diabetes mellitus (T2DM).5,54 On the other hand, in 
patients with impaired glucose tolerance (IGT) or impaired 
fasting glucose (IFG), weight loss resulting from lifestyle 
measures reduced the risk for developing T2DM.55,56 More 
importantly, intentional weight loss in overweight diabetic 
patients reduced cardiovascular and all cause mortality.57,58 
In several studies in obese or overweight diabetic patients, 
sibutramine (5–20 mg/day for 12 weeks to six months) 
reduced body weight, BMI, waist circumference and body 
fat more than placebo.59–62 Quality of life also improved in 
the sibutramine group, particularly in patients who lost 5% 
body weight.61 In a longer-term study, 59 overweight or obese 
diabetic were treated with meal replacement products and 
intermittent low-calorie diet and were randomized to receive Vascular Health and Risk Management 2009:5 444
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sibutramine for two years or only sibutramine during the 
second year of the study.63 Body weight reduction was similar 
in the two groups and there was no further weight loss during 
the second year of sibutramine treatment.63 Meta-analyses 
suggested that weight loss with sibutramine is similar in 
diabetic and nondiabetic obese patients.34,64 In the study by 
Rucker and colleagues34 placebo subtracted weight losses 
in patients with T2DM averaged 5% and the respective rate 
in nondiabetic patients was 4.3%. Another meta-analysis in 
patients with T2DM showed that sibutramine resulted in a 
weight reduction averaging -3.3% and a modest decrease of 
glycosylated hemoglobin (HbA1c) by -0.7%.65
Sibutramine-induced weight loss is accompanied with 
improvements in lipid profile and, in earlier studies, mainly 
a substantial increase in high-density lipoprotein cholesterol 
(HDL-C) levels was observed.28,31,32,37 In the STORM study,37 
sibutramine treatment for 24 months increased HDL-C 
levels more in men than in women (11.2% vs 8.5% more 
than placebo, respectively) and similar improvements were 
reported in a 12 month study by Abfelbaum et al38 The rise in 
HDL-C levels was suggested to be greater than that expected 
to result from weight loss.37 In two recent meta-analyses 
however, it was evident that the effect of the drug on HDL-C 
was not so important. HDL-C levels increased by 2.53%66 
and 0.04 mmol/l34 more than placebo and these changes 
were probably attributable to the weight loss. A decrease in 
triglycerides (TG) levels was reported in some sibutramine 
studies28,32,37 but not in others.31,33,42 The reduction in TG levels 
also correlated with the weight loss.37 A fall in low-density 
lipoprotein cholesterol (LDL-C) levels was also described28 
but this was not confirmed by most reports.31–33,37,42 In a 
recent meta-analysis sibutramine reduced TG levels more 
than placebo by 0.2 mmol/l.34 Changes in LDL-C and HbA1c 
levels did not differ between groups.34 Similar changes in 
lipid profile are observed in diabetic patients treated with 
sibutramine but there is also an improvement in glycemic 
control in this population.67
Elevated serum uric acid levels is frequently present 
in obese patients and might be associated with increased 
vascular risk.68 In some studies, sibutramine lowered serum 
uric acid levels27,28,38 and this reduction was proportional to 
weight loss.27
Insulin resistance (IR) coexists very often with central 
obesity and weight loss may ameliorate this condition and 
associated metabolic disorders.69 In a weight loss nonrandom-
ized study,70 sibutramine ameliorated IR parameters includ-
ing serum insulin, homeostasis model assessment (HOMA) 
index, serum free fatty acids and TG, before any significant 
change of body weight and fat distribution suggesting that, 
sibutramine might improve insulin sensitivity directly. Other 
studies, however, did not confirm this finding but demon-
strated that the improvement in IR by the drug was dependent 
on weight reduction per se.71,72 Until now, a direct action of 
sibutramine on IR is not proven.
Nonalcoholic fatty liver disease is frequently present in 
overweight and obese patients and may progress to nonalco-
holic steatohepatitis (NASH) or cirrhosis.73 The fundamental 
derangement in nonalcoholic fatty liver disease is IR. In 
patients with NASH, sibutramine reduced transaminase 
and γ-glutamyltransferase levels and induced a regression 
in ultrasonography-assessed steatosis.74
Inflammation plays an important role in the pathogenesis 
of atherosclerosis.75 Overweight and obese patients frequently 
have elevated levels of inflammatory markers.76–79 Sibutra-
mine reduced high sensitivity C-reactive protein (hsCRP) 
levels in some studies80,81 but not in others.82 Sibutramine 
along with diet and exercise reduced the serum levels of the 
pro-inflammatory cytokines tumor necrosis factor α (TNFα) 
and interleukin 6 (IL-6) and increased the serum levels of the 
anti-inflammatory cytokine IL-10.83 These anti-inflammatory 
effects were independent of weight loss in some studies80 but 
were related to weight loss in others.81,83
Leptin, adiponectin, and resistin are important adipokines 
and play a role in energy homeostasis, glucose metabo-
lism, and weight regulation.84 In some studies, sibutramine 
reduced serum resistin and leptin levels and increased serum 
adiponectin levels25,81,83,85 and these effects were associated 
with improvements in IR and metabolic risk factors.81,83 The 
observed changes in adipokine levels also correlated with 
weight loss.25,81,83 However, sibutramine did not affect leptin 
or adiponectin levels in other reports.82,86,87
Endothelial dysfunction might represent an early stage 
of the atherosclerotic process.75 Endothelial dysfunction is 
frequently present in obese patients and correlates with the 
degree of abdominal obesity.88,89 In 80 obese patients with 
coronary heart disease (CHD), sibutramine (10 mg/day for 
four months) improved endothelial function.80 The improve-
ment in endothelial function correlated with the decrease in 
hsCRP levels but not with the change in body weight.80
Left ventricular hypertrophy (LVH) is associated with 
increased vascular and all cause mortality in hypertensive 
patients90 and in the general population.90,91 In hypertensive 
patients, regression of LVH with antihypertensive treatment 
reduces vascular risk.92 LVH appears to be more prevalent in 
obese patients than in subjects with normal weight regard-
less of the presence of hypertension.93,94 In obese patients, Vascular Health and Risk Management 2009:5 445
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sibutramine (10–20 mg/day for 3–6 months) reduced left 
ventricular mass whereas no significant change was observed 
in the placebo group.95,96 This reduction correlated with the 
decrease in body weight.95
Therapeutic use of sibutramine 
in obesity-related disorders
Obstructive sleep apnea is a disorder frequently observed 
in obese patients and is associated with increased risk for 
developing hypertension.97,98 In an uncontrolled study in 
87 obese patients, sibutramine (10 mg/day for six months) 
reduced body weight and improved markers of obstruc-
tive sleep apnea severity (respiratory disturbance index 
and Epworth score).99 There was a significant correlation 
between weight loss and the improvement in obstructive 
sleep apnea markers.99 In a smaller, shorter-term, placebo-
controlled study (20 patients with obstructive sleep apnea 
given sibutramine 15 mg/day for one month) sibutramine had 
no effect on polysomnographic variables (sleep efficiency 
and apnea–hypopnea index).100 However, no change in body 
weight was observed in this study.100
Polycystic ovary syndrome (PCOS) is a complex, frequent 
condition affecting 5%–10% of premenopausal women, 
characterized by hyperandrogenemia, hirsutism and oligo-
menorrhea or amenorrhea. A substantial proportion of these 
patients are overweight or obese and insulin resistant, and 
are at high risk for subsequent cardiovascular disease.101 In 
two small studies in overweight or obese women with PCOS 
(total n = 101), sibutramine (10–15 mg/day for six months) 
reduced body weight and BMI more than lifestyle modifica-
tion alone.102,103 Triglyceride levels and markers of androgen 
excess decreased more in the sibutramine group but menstrual 
frequency did not differ significantly between groups.102,103 In 
one of these studies insulin sensitivity was also increased.102 
In another study in 40 obese women with PCOS, sibutra-
mine (10 mg/day) reduced body weight, BMI and markers 
of androgen excess to a similar extent as oral ethinyl estra-
diol plus cyproterone acetate (35 µg/2 mg).104 However, 
only sibutramine reduced WHR and improved insulin 
sensitivity.104 On the other hand, HDL-C levels increased 
in the ethinyl estradiol plus cyproterone acetate group but 
remained stable in the sibutramine group.104 Combining 
sibutramine and ethinyl estradiol plus cyproterone acetate did 
not provide further benefits over sibutramine monotherapy 
except for an increase in HDL-C levels.104 Despite these 
promising findings, it should be noted that sibutramine is 
contraindicated during pregnancy and should be discontinued 
in these patients in case of pregnancy. Overall, preliminary 
data suggest that sibutramine in women with PCOS could 
represent a therapeutic option, provided that its use is moni-
tored carefully.
The use of several antipsychotic agents is associated with 
significant weight gain.105 In a study in 37 obese or overweight 
patients with schizophrenia or schizoaffective disorder treated 
with olanzapine, sibutramine (5–15 mg/day for 12 weeks) 
reduced body weight, BMI, and waist circumference 
more than placebo.106 However, three months after the end 
of the study, changes from baseline in all these param-
eters were similar in the two groups.106 In two other reports, 
sibutramine (5–20 mg/day for 12 weeks) did not reduce 
body weight more than placebo in patients with chronic 
schizophrenia treated with olanzapine (n = 28) when 
combined with metformin (850–1700 mg/day)107 or in obese 
patients with schizophrenia or schizoaffective disorder treated 
with clozapine (n = 21) when given alone.108
Binge eating disorder is characterized by recurrent 
binge eating in the absence of inappropriate compensatory 
behaviors and/or extreme dietary restraint and is distin-
guishable from both bulimia nervosa and obesity.109 Binge 
eating disorder very often results in overweight and obesity. 
Sibutramine appears to be useful in the management of 
these patients. An early, uncontrolled study in 10 patients 
reported a reduction in body weight and in the number of 
binge eating episodes when sibutramine (15 mg/day) was 
given for 12 weeks.110 In placebo-controlled studies (total n = 
384), sibutramine (10–15 mg/day for 12–24 weeks) reduced 
body weight and the frequency of binge eating episodes more 
than placebo.111–113 In one report, depression scores were also 
reduced more in the sibutramine group.111
Finally, sibutramine was administered in a small group 
of obese adults with hypopituitary disease for 11 months.114 
It was previously shown that substituted patients with 
hypopituitarism have lower sympathoadrenal activity but a 
normal energy expenditure when compared with controls.115 
Therefore, the rationale for using sibutramine in such patients 
was that, besides reducing food intake, it could enhance 
sympathoadrenal activity and, thus, induce an adequate 
weight loss.114 The results of the study showed that obese 
patients with hypopituitary disease exhibited the same favor-
able changes in anthropometric indices, body composition 
and metabolic parameters as controls with simple obesity.
The case of childhood obesity
The prevalence of childhood obesity has increased 
dramatically during the last decades116 and, in the US, current 
prevalence of overweight in children and adolescents reaches Vascular Health and Risk Management 2009:5 446
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approximately 31.9% and that of obesity 16.3%.117 Similar 
rates were reported in other countries.116,118 In cross-sectional 
studies in children and adolescents, overweight is associated 
with increased prevalence of IFG, T2DM, hypertension, and 
dyslipidemia.120,121 A significant proportion of overweight 
children and adolescents will become obese adults.122,123 More 
importantly, overweight and obese children and adolescents 
have increased risk for CHD and all cause mortality.124,125 
Sibutramine might be useful in obese adolescents.17,126–131 
In an early placebo-controlled trial in 82 obese adolescents 
receiving behavior therapy and sibutramine (starting dose 
5 mg/day and uptitrated to 15 mg/day) the authors demon-
strated a weight reduction significantly higher in the 
sibutramine group than in the placebo group (by 4.6 kg) 
after six months.17 All participants received sibutramine for 
the following six months.17 Those who continued to receive 
sibutramine gained a mean of 0.8 kg whereas those who 
were switched from placebo to sibutramine lost a mean of 
1.3 kg (p = 0.057 between groups).17 Interestingly, there 
was no difference in weight loss at 12 months between 
patients given sibutramine for 12 months and those given 
sibutramine for six months.17 In another study in 60 obese 
adolescents, sibutramine (10 mg/day given for six months) 
reduced body weight and BMI by a mean of 7.9 kg and 
2.7 kg/m2 respectively more than placebo (p  0.001).127 
Changes in lipid profile and IR did not differ between groups 
in any of these two studies.17,127 In a more recent and larger 
study in 498 obese adolescents receiving behavior therapy, 
sibutramine (10 mg/day uptitrated to 15 mg/day at six months 
if BMI was not reduced by 10%) reduced body weight by 
a mean of 8.4 kg and BMI by a mean of 2.9 kg/m2 more than 
placebo after 12 months.126 There was also a greater reduc-
tion in TG levels and in IR and a larger increase in HDL-C 
levels in the sibutramine group.126 A recent meta-analysis 
reported a 2.4 kg/m2 (with a 95% confidence interval [CI] of 
1.8–3.1) in BMI loss when sibutramine was given to obese 
adolescents.128 In this meta-analysis, adolescents taking the 
drug had higher rates of elevated blood pressure (BP) and 
pulse rate than adolescents taking placebo.128
The usefulness of sibutramine was tested in children 
with hypothalamic obesity. These patients have multiple 
pituitary hormone deficiencies due to hypothalamic genetic 
disorders or hypothalamic damage from tumor, surgery and/
or irradiation, resulting in intractable weight gain resistant 
to conventional therapeutic measures.129 Although different 
therapeutic strategies have been attempted in hypothalamic 
obesity, successful treatment has been rarely achieved.129,130 
In a placebo-controlled study in 50 children and adolescents, 
7–20 years of age, with hypothalamic obesity or obesity 
with aggravating syndromes (mental retardation, autism 
or attention deficiency hyperactivity disorder), sibutramine 
(10–15 mg/day for 20 weeks) reduced BMI SD score value 
significantly as well as body fat and was well tolerated.131 
However, discontinuation of sibutramine was followed by 
regain of 60% of the weight loss.131
It should be noted that sibutramine is currently indicated 
only in patients 16 years of age. Moreover, current guide-
lines recommend lifestyle measures as first-line treatment 
in obese children and adolescents.132 If these modifications 
are ineffective, medication can be considered in specialized 
centers in children 11 years of age with BMI of 95th 
percentile and significant comorbidities or with BMI 
of 99th percentile.132
Comparative studies 
with other antiobesity agents
Sibutramine and orlistat are the only approved agents for the 
long-term management of obesity and a number of studies 
compared these agents. Sibutramine (10–20 mg/day for 
12 weeks to 12 months) reduced body weight and BMI more 
than orlistat (360 mg/day) in three studies in obese patients 
(total n = 325).133–135 However, in two other studies (total 
n = 259), sibutramine (10 mg/day given for 12–24 weeks) 
and orlistat (360 mg/day) induced similar reductions in body 
weight, BMI, and waist circumference.136,137 In another study 
in 115 hypertensive obese patients, sibutramine (10 mg/day 
given for 12 months) and orlistat (360 mg/day) reduced 
body weight, BMI, waist circumference and WHR to a similar 
extent.138 A recent meta-analysis of seven studies comparing 
head-to head sibutramine with orlistat (n = 851) reported a 
2.2 kg greater weight loss with sibutramine.139 Changes in 
lipid profile appear to be similar with these two agents.135,136,138 
However, there was a greater improvement in depression 
score in patients assigned to sibutramine.137 In most studies, 
BP fell in the orlistat group and did not change or increased 
in the sibutramine group.135,136,138,140 However, total adverse 
events were fewer in the sibutramine-allocated group.138,140
Combining sibutramine and orlistat (10  mg and 360  mg/day, 
respectively, for 3–6 months) did not provide additional 
benefits over sibutramine monotherapy in obese patients.133,134 
Interestingly, a small study in 34 women who had received 
sibutramine for one year showed that adding orlistat to 
sibutramine for 16 weeks did not induce further weight 
loss.141 In another study in 198 obese patients, combining 
sibutramine with an experimental selective antagonist of the 
receptor 5 of the orexigenic neuropeptide Y did not result Vascular Health and Risk Management 2009:5 447
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in additional weight loss compared with sibutramine alone 
after 24 weeks.136
Safety considerations
Obesity increases the risk for developing hypertension.5,142,143 
In addition, hypertension is more prevalent in overweight 
and obese individuals. Weight loss resulting from lifestyle 
modifications lowers BP and also reduces the risk for devel-
oping hypertension.144,145 In contrast, sibutramine increased 
BP levels compared with placebo in several trials despite 
the reduction in body weight.37,62 Other studies reported 
an increase only in diastolic BP (DBP) and not in systolic 
BP (SBP)27,146 and some no change in BP levels.42,44,59–61 
A meta-analysis reported a significant increase in SBP and 
DBP levels (by 1.6 and 2.4 mmHg, respectively) in patients 
treated with sibutramine.34 Another meta-analysis reported 
that the increase in both SBP and DBP appears to be greater 
when the initial body weight is 92 kg.29
Sibutramine increases BP levels due to a peripheral sym-
pathomimetic effect.146–149 Sibutramine stimulated the expres-
sion of α2 and β1 adrenoreceptor genes in adipose tissue and 
increased plasma epinephrine and norepinephrine levels.142 
Interestingly, sibutramine also exerts a central sympatholytic 
action, which might blunt its peripheral sympathomimetic 
effects.146–149
Sibutramine (10–20 mg/day for 12–52 weeks) was 
administered to hypertensive patients in several clinical 
studies and reduced body weight, BMI, waist circumfer-
ence and WHR more than placebo.87,138,150–153 In addition, 
sibutramine reduced TG and uric acid levels and increased 
HDL-C levels.150,151,153 Quality of life also improved in the 
sibutramine group.150 In a recent meta-analysis of sibutramine 
studies in hypertensive patients, sibutramine reduced body 
weight by 3.7 kg more than placebo.154 Subgroup analyses 
in other meta-analyses suggested that weight loss with 
sibutramine is similar in hypertensive and normotensive 
obese patients.34,64 Even though sibutramine increased BP 
when given to hypertensive patients,150–152 it did not com-
promise BP control when hypertension was well controlled 
with angiotensin-converting enzyme inhibitors,151 calcium 
channel blockers,150 or beta blockers.152 It was also reported 
that the sibutramine-induced increase in BP is not greater in 
hypertensive patients.146 However, it should be emphasized 
that regular monitoring of BP and pulse rate is recommended 
in patients given sibutramine. In addition, sibutramine should 
be given with caution in patients with controlled hyperten-
sion and is contraindicated in patients with uncontrolled 
hypertension.
Increased heart rate is another side effect of sibutramine 
and was observed in most studies.27,32,33,37,59,61 A meta-analysis 
reported an increase in pulse rate by 4.5 beats/min in sibutra-
mine-treated patients.34 In the general population, elevated 
heart rate is associated with increased vascular risk.155,156 but 
it is not clear whether the sibutramine-induced increase in 
heart rate is also harmful.
Recently, treatment with sibutramine was associated in 
rare cases with QT interval prolongation which could lead 
to ventricular fibrillation and cardiac arrest.157,158 Therefore, 
monitoring of the electrocardiogram might be indicated in 
patients treated with sibutramine.157 In addition, concomitant 
use of sibutramine with other drugs likely to prolong QT 
(eg, certain antipsychotics, antidepressants, and antiarrhyth-
mic agents) should probably be avoided.157
Dry mouth, constipation, nausea, and insomnia are other 
side effects of sibutramine.27,30,31,34
Overall, sibutramine is contraindicated in patients with 
established coronary heart disease, previous stroke, heart 
failure, or cardiac arrhythmias.30 In addition, it should not be 
administered to patients receiving monoamine oxidase inhibi-
tors, selective serotonin reuptake inhibitors, sumatriptan, 
dihydroergotamine, meperidine, methadone, pentazocine, 
fentanyl, lithium or tryptophan.13,30 However, a Swedish study 
reported that 28% of the patients prescribed sibutramine had 
one or more contraindications to its use.47
In the larger sibutramine studies, discontinuation rates 
at one and two years of treatment were 19%–49% and 42%, 
respectively.27,37,44 Drop-out rates at one and two years were 
similarly high in the placebo groups in the latter studies 
(27%–51% and 50%, respectively).27,37,44 Interestingly, a 
population-based study suggested that these rates might 
be even higher in clinical practice.159 Persistence rates at 
six months, one and two years were 26%, 8%, and 2%, 
respectively.159 In the same study, approximately 60% of 
the patients did not fill in a second prescription of sibutra-
mine. 159 In other population studies, 41.8%–59.1% of the 
patients had stopped sibutramine within three months of 
starting treatment.160,161 Besides side effects, perceived low 
efficacy and cost might explain these high discontinuation 
rates.159–161
The ongoing Sibutramine Cardiovascular Outcome Trial 
(SCOUT) will assess the effect of sibutramine (10–15 mg/day) 
on vascular events in 9,000 obese and overweight patients 
with either established vascular disease or T2DM and another 
vascular risk factor.162 Preliminary safety results showed 
that sibutramine was safe and well tolerated in this high-risk 
population.163Vascular Health and Risk Management 2009:5 448
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The effects of sibutramine on weight loss and on associated 
risk factors and diseases are summarized in the Table 1.
Conclusions
Sibutramine, a selective inhibitor of central neuronal reuptake 
of serotonine and noradrenaline, reduces food intake and 
body weight more than placebo and has beneficial effects on 
the lipid profile, glycemic control and inflammatory markers 
in studies for up to one year. The drug may be beneficial in 
obese patients with metabolic disturbances in cases where 
a lack of satiety or frequent snacking is an obstacle and 
limits weight reduction. Preliminary studies showed that 
sibutramine could be used in specific pathological situations 
such as polycystic ovary syndrome, sleep apnea syndrome, 
hypothalamic obesity and in obese adolescents. However, 
the increase in BP and pulse rate raises safety concerns. The 
high discontinuation rate should also be noticed. Another 
major limitation of sibutramine is that significant weight 
regain is frequently observed after treatment discontinuation. 
This implies that treatment with this agent should be long 
term, if not lifelong, if we aspire to sustained reductions in 
weight. However, most of the weight loss during sibutramine 
treatment occurs during the first six months of treatment and 
little additional weight loss is observed afterwards. Moreover, 
there are no sibutramine studies longer than two years and 
accordingly sibutramine is approved for use only for a limited 
period of time. Finally, it is unclear whether treatment with 
sibutramine will reduce cardiovascular events.
Until more conclusive evidence on the efficacy and safety 
of sibutramine are available, lifestyle measures should remain 
the mainstay of the management of obesity.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  James WP. The epidemiology of obesity: the size of the problem. 
J Intern Med. 2008;263(4):336–352.
  2.  Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, 
Flegal KM. Prevalence of overweight and obesity in the United States, 
1999–2004. JAMA. 2006;295(13):1549–1555.
  3.  Tzotzas T, Krassas GE. Prevalence and trends of obesity in children 
and adults of South Europe. Pediatr Endocrinol Rev. 2004;1 Suppl 3: 
448–454.
  4.  Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. 
Overweight and obesity as determinants of cardiovascular risk: the 
Framingham experience. Arch Intern Med. 2002;162(16):1867–1872.
  5.  Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable 
risk factors associated with myocardial infarction in 52 countries 
(the INTERHEART study): case-control study. Lancet. 2004;364 
(9438):937–952.
  6.  Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass 
index and mortality in a prospective cohort of US adults. N Engl J Med. 
1999;341(15):1097–1105.
  7.  Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years 
of life lost due to obesity. JAMA. 2003;289(2):187–193.
  8.  Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, 
Bonneux L. Obesity in adulthood and its consequences for life expec-
tancy: a life-table analysis. Ann Intern Med. 2003(1);138:24–32.
  9.  Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic 
and surgical management of obesity in primary care: a clinical practice 
guideline from the American College of Physicians. Ann Intern Med. 
2005;142(7):525–531.
10.  Bray GA, Greenway FL. Pharmacological treatment of the overweight 
patient. Pharmacol Rev. 2007;59(2):151–184.
11.  Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity 
target? Nat Rev Drug Discov. 2008;7(12):961–962.
Table 1 effects of sibutramine on obesity and related disorders
Anthropometric parameters Effect
Body weight ↓
Body mass index ↓
waist circumference ↓
waist/hip ratio ↓






HbA1c levels ↓ (in diabetic patients)
Serum uric acid levels ↓
Inflammatory markers
High-sensitivity C-reactive protein ↓
Pro-inflammatory cytokines  
(TNF-α, iL-6)
↓
Anti-inflammatory cytokines (IL-10) ↑
Serum adipokine levels
Leptin ↓ or →
Adiponectin ↑ or →
Resistin ↓
endothelial function (+)





Sleep apnea syndrome Possible (+)
Polycystic ovary syndrome (+)
Binge eating disorder (+)
Hypothalamic obesity Possible (+)
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; TNF-α, 
tumor necrosis factor-α; HbA1c, glycosylated hemoglobin  A1; iL-6, interleukin-6; iL-10, 
interleukin-10; →, no effect; ↓, decrease; ↑, increase; (+), improvement.Vascular Health and Risk Management 2009:5 449
Sibutramine in obesity and related disorders Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
12.  Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, 
Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med 
Res Opin. 2005;21(3):457–468.
13.  Sharma B, Henderson DC. Sibutramine: current status as an anti-
obesity drug and its future perspectives. Expert Opin Pharmacother. 
2008;9(12):2161–2173.
14.  Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food 
intake in non-dieting women with obesity. Obes Res. 1998;6(1):1–11.
15.  Barkeling B, Elfhag K, Rooth P, Rossner S. Short-term effects of sibutra-
mine (Reductil) on appetite and eating behaviour and the long-term thera-
peutic outcome. Int J Obes Relat Metab Disord. 2003;27(6):693–700.
16.  Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. Thermo-
genic effects of sibutramine in humans. Am J Clin Nutr. 1998;68(6): 
1180–1186.
17.  Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior 
therapy and sibutramine for the treatment of adolescent obesity: 
a randomized controlled trial. JAMA. 2003;289(14):1805–1812.
18.  Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect 
of sibutramine on energy expenditure and appetite during chronic 
treatment without dietary restriction. Int J Obes Relat Metab Disord. 
1999;23(10):1016–1024.
19.  Hainer V, Kunesova M, Bellisle F, Hill M, Braunerova R, Wagenknecht M. 
Psychobehavioral and nutritional predictors of weight loss in obese 
women treated with sibutramine. Int J Obes (Lond). 2005;29(2):208–216.
20.  Van Mil EG, Westerterp KR, Kester AD, Delemarre-van de Waal HA, 
Gerver WJ, Saris WH. The effect of sibutramine on energy expenditure 
and body composition in obese adolescents. J Clin Endocrinol Metab. 
2007;92(4):1409–1414.
21.  Walsh KM, Leen E, Lean ME. The effect of sibutramine on resting 
energy expenditure and adrenaline-induced thermogenesis in obese 
females. Int J Obes Relat Metab Disord. 1999;23(10):1009–1015.
22.  Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on rest-
ing metabolic rate and weight loss in overweight women. Obes Res. 
1998;6(2):115–121.
23.  Levin BE, Dunn-Meynell AA. Sibutramine alters the central mechanisms 
regulating the defended body weight in diet-induced obese rats. Am J 
Physiol Regul Integr Comp Physiol. 2000;279(6):R2222–R2228.
24.  Baranowska B, Wolin ´ska-Witort E, Martyn ´ska L, et al. Sibutramine 
therapy in obese women – effects on plasma neuropeptide Y (NPY), 
insulin, leptin and beta-endorphin concentrations. Neuro Endocrinol 
Lett. 2005;26(6):675–679.
25.  Rodrigues AM, Radominski RB, Suplicy Hde L, De Almeida SM, 
Niclewicz PA, Boguszewski CL. The cerebrospinal fluid/serum leptin 
ratio during pharmacological therapy for obesity. J Clin Endocrinol 
Metab. 2002;87(4):1621–1626.
26.  Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy 
and tolerability of sibutramine in obese patients: a dose-ranging study. 
Int J Obes Relat Metab Disord. 1998;22(1):32–38.
27.  Smith IG, Goulder MA. Randomized placebo-controlled trial of long-
term treatment with sibutramine in mild to moderate obesity. J Fam 
Pract. 2001;50(6):505–512.
28.  Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces 
dose-related weight loss. Obes Res. 1999;7(2):189–198.
29.  Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight 
loss and blood pressure: a meta-analysis of controlled trials. Obes Res. 
2003;11(9):1116–1123.
30.  Klein S, Burke LE, Bray GA, et al; for the American Heart Association 
Council on Nutrition, Physical Activity, and Metabolism. Clinical 
implications of obesity with specific focus on cardiovascular disease: 
a statement for professionals from the American Heart Association 
Council on Nutrition, Physical Activity, and Metabolism: endorsed 
by the American College of Cardiology Foundation. Circulation. 
2004;110(18):2952–2967.
31.  Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Effects of sibutra-
mine on body weight and serum lipids: a double-blind, randomized, 
placebo-controlled study in 322 overweight and obese patients with 
dyslipidemia. Am Heart J. 2001;142(3):489–497.
32.  Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K; for 
Study Group SA; SAT Study. Weight reduction by sibutramine in obese 
subjects in primary care medicine: the SAT Study. Exp Clin Endocrinol 
Diabetes. 2004;112(4):201–207.
33.  Porter JA, Raebel MA, Conner DA, et al. The Long-term Outcomes of 
Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating 
the role of drug therapy within a weight management program in a 
group-model health maintenance organization. Am J Manag Care. 
2004;10(6):369–376.
34.  Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharma-
cotherapy for obesity and overweight: updated meta-analysis. BMJ. 
2007;335(7631):1194–1199.
35.  Van Gaal LF, Wauters MA, Peiffer FW, De Leeuw IH. Sibutramine 
and fat distribution: is there a role for pharmacotherapy in abdominal/
visceral fat reduction? Int J Obes Relat Metab Disord. 1998;22 Suppl 1:
S38–S40.
36.  Kamel EG, McNeill G, Van Wijk MC. Change in intra-abdominal 
adipose tissue volume during weight loss in obese men and women: 
correlation between magnetic resonance imaging and anthropo-
metric measurements. Int J Obes Relat Metab Disord. 2000;24(5): 
607–613.
37.  James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight 
maintenance after weight loss: a randomised trial. STORM Study 
Group. Sibutramine Trial of Obesity Reduction and Maintenance. 
Lancet. 2000;356(9248):2119–2125.
38.  Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. 
Long-term maintenance of weight loss after a very-low-calorie diet: 
a randomized blinded trial of the efficacy and tolerability of sibutramine. 
Am J Med. 1999;106(2):179–184.
39.  Mathus-Vliegen EM. Long-term maintenance of weight loss with 
sibutramine in a GP setting following a specialist guided very-low-
calorie diet: a double-blind, placebo-controlled, parallel group study. 
Eur J Clin Nutr. 2005;59 Suppl 1:S31–S38.
40.  Turk MW, Yang K, Hravnak M, Sereika SM, Ewing LJ, Burke LE. Ran-
domized clinical trials of weight loss maintenance: a review. J Cardiovasc 
Nurs. 2009;24(1):58–80.
41.  Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. 
Benefits of lifestyle modification in the pharmacologic treatment of 
obesity: a randomized trial. Arch Intern Med. 2001;161(2):218–227.
42.  Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of 
lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 
2005;353(20):2111–2120.
43.  Phelan S, Wadden TA, Berkowitz RI, et al. Impact of weight loss on 
the metabolic syndrome. Int J Obes (Lond). 2007;31(9):1442–1448.
44.  Wirth A, Krause J. Long-term weight loss with sibutramine: a random-
ized controlled trial. JAMA. 2001;286(11):1331–1339.
45.  Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response 
to sibutramine therapy in obese non-diabetic and diabetic patients. 
Diabetes Obes Metab. 2006;8(2):206–213.
46.  Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutra-
mine, and rimonabant. Lancet. 2007;369(9555):71–77.
47.  Dahlin A, Beermann B. Incorrect use of orlistat and sibutramine in 
clinical practice. Eur J Clin Pharmacol. 2007;63(2):205–209.
48.  Hansen D, Astrup A, Toubro S, et al; Goulder For The STORM Study 
Group M. Predictors of weight loss and maintenance during 2 years 
of treatment by sibutramine in obesity. Results from the European 
multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and 
Maintenance. Int J Obes Relat Metab Disord. 2001;25(4):496–501.
49.  Elfhag K, Rossner S, Barkeling B, Rooth P. Sibutramine treatment in 
obesity: initial eating behaviour in relation to weight loss results and 
changes in mood. Pharmacol Res. 2005;51(2):159–163.
50.  Elfhag K, Finer N, Rossner S. Who will lose weight on sibutramine 
and orlistat? Psychological correlates for treatment success. Diabetes 
Obes Metab. 2008;10(6):498–505.
51.  Peters WR, MacMurry JP, Walker J, Giese RJ Jr, Comings DE. Phenyl-
ethanolamine N-methyltransferase G-148A genetic variant and weight 
loss in obese women. Obes Res. 2003;11(3):415–419.Vascular Health and Risk Management 2009:5 450
Tziomalos et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
52.  Hauner H, Meier M, Jockel KH, Frey UH, Siffert W. Prediction 
of successful weight reduction under sibutramine therapy through 
genotyping of the G-protein beta3 subunit gene (GNB3) C825T poly-
morphism. Pharmacogenetics. 2003;13(8):453–459.
53.  Grudell AB, Sweetser S, Camilleri M, et al. A controlled pharmacoge-
netic trial of sibutramine on weight loss and body composition in obese 
or overweight adults. Gastroenterology. 2008;135(4):1142–1154.
54.  Weinstein AR, Sesso HD, Lee IM, et al. Relationship of physical activity 
vs body mass index with type 2 diabetes in women. JAMA. 2004;292(10): 
1188–1194.
55.  Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the 
incidence of type 2 diabetes with lifestyle intervention or metformin. 
N Engl J Med. 2002;346(6):393–403.
56.  Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 
diabetes mellitus by changes in lifestyle among subjects with impaired 
glucose tolerance. N Engl J Med. 2001;344(18):1343–1350.
57.  Gregg EW, Gerzoff RB, Thompson TJ, Williamson DF. Trying to lose 
weight, losing weight, and 9-year mortality in overweight US adults 
with diabetes. Diabetes Care. 2004;27(3):657–662.
58.  Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. 
Intentional weight loss and mortality among overweight individuals 
with diabetes. Diabetes Care. 2000;23(10):1499–1504.
59.  Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is 
effective for weight loss and diabetic control in obesity with type 2 dia-
betes: a randomised, double-blind, placebo-controlled study. Diabetes 
Obes Metab. 2000;2(2):105–112.
60.  Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutra-
mine in the treatment of obese Type 2 diabetic patients receiving 
sulphonylurea therapy. Diabet Med. 2002;19(2):119–124.
61.  Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine 
improves glycaemic control and other metabolic parameters in obese 
patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2000;2(3): 
175–187.
62.  McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the 
management of obese type 2 diabetic patients treated with metformin. 
Diabetes Care. 2003;26(1):125–131.
63.  Redmon JB, Reck KP, Raatz SK, et al. Two-year outcome of a 
combination of weight loss therapies for type 2 diabetes. Diabetes Care. 
2005;28(6):1311–1315.
64.  Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of 
sibutramine for weight loss: a systematic review. Arch Intern Med. 2004; 
164(9):994–1003.
65.  Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy 
for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. 
Arch Intern Med. 2004;164(13):1395–1404.
66.  Mannucci E, Dicembrini I, Rotella F, Rotella CM. Orlistat and sibutramine 
beyond weight loss. Nutr Metab Cardiovasc Dis. 2008;18(5):342–348.
67.  Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine 
on weight management and metabolic control in type 2 diabetes: a meta-
analysis of clinical studies. Diabetes Care. 2005;28(4):942–949.
68.  Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid 
levels and vascular disease. Curr Med Res Opin. 2004;20(6):951–954.
69.  Pi-Sunyer FX. A review of long-term studies evaluating the efficacy 
of weight loss in ameliorating disorders associated with obesity. Clin 
Ther. 1996;18(6):1006–1035.
70.  Kim DM, Yoon SJ, Ahn CW, et al. Sibutramine improves fat distribu-
tion and insulin resistance, and increases serum adiponectin levels in 
Korean obese nondiabetic premenopausal women. Diabetes Res Clin 
Pract. 2004;66 Suppl 1:S139–S144.
71.  McLaughlin T, Abbasi F, Lamendola C, Kim HS, Reaven GM. 
Metabolic changes following sibutramine-assisted weight loss in obese 
individuals: role of plasma free fatty acids in the insulin resistance of 
obesity. Metabolism. 2001;50(7):819–824.
72.  Tambascia MA, Geloneze B, Repetto EM, Geloneze SR, Picolo M, 
Magro DO. Sibutramine enhances insulin sensitivity ameliorating 
metabolic parameters in a double-blind, randomized, placebo-controlled 
trial. Diabetes Obes Metab. 2003;5(5):338–344.
73.  Parekh S, Anania FA. Abnormal lipid and glucose metabolism in 
obesity: implications for nonalcoholic fatty liver disease. Gastroenter­
ology. 2007;132(6):2191–2207.
74.  Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects 
of sibutramine and orlistat on the ultrasonographic findings, insulin 
resistance and liver enzyme levels in obese patients with non-alcoholic 
steatohepatitis. Rom J Gastroenterol. 2003;12(3):189–192.
75.  Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 
1999;340(2):115–126.
76.  Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated 
C-reactive protein levels in overweight and obese adults. JAMA. 
1999;282(22):2131–2135.
77.  Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 
are reduced in serum and subcutaneous adipose tissue of obese women 
after weight loss. J Clin Endocrinol Metab. 2000;85(9):3338–3342.
78.  Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, 
Haffner SM. Chronic subclinical inflammation as part of the insulin 
resistance syndrome: the Insulin Resistance Atherosclerosis Study 
(IRAS). Circulation. 2000;102(1):42–47.
79.  Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-reactive 
protein with measures of obesity, insulin resistance, and subclinical 
atherosclerosis in healthy, middle-aged women. Arterioscler Thromb 
Vasc Biol. 1999;19(8):1986–1991.
80.  Shechter M, Beigel R, Freimark D, Matetzky S, Feinberg MS. Short-
term sibutramine therapy is associated with weight loss and improved 
endothelial function in obese patients with coronary artery disease. 
Am J Cardiol. 2006;97(11):1650–1653.
81.  Valsamakis G, McTernan PG, Chetty R, et al. Modest weight loss and 
reduction in waist circumference after medical treatment are associ-
ated with favorable changes in serum adipocytokines. Metabolism. 
2004;53(4):430–434.
82.  Hung YJ, Chen YC, Pei D, et al. Sibutramine improves insulin sensi-
tivity without alteration of serum adiponectin in obese subjects with 
Type 2 diabetes. Diabet Med. 2005;22(8):1024–1030.
83.  Jung SH, Park HS, Kim KS, et al. Effect of weight loss on some serum 
cytokines in human obesity: increase in IL-10 after weight loss. J Nutr 
Biochem. 2008;19(6):371–375.
84.  Ahima RS, Osei SY. Adipokines in obesity. Front Horm Res. 2008;36: 
182–197.
85.  Quilliot D, Bohme P, Zannad F, Ziegler O. Sympathetic-leptin relationship 
in obesity: effect of weight loss. Metabolism. 2008;57(4):555–562.
86.  Abbasi F, Lamendola C, McLaughlin T, Hayden J, Reaven GM, 
Reaven PD. Plasma adiponectin concentrations do not increase in 
association with moderate weight loss in insulin-resistant, obese women. 
Metabolism. 2004;53(3):280–283.
87.  Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea Ferreira SR, 
Zanella MT. Effects of sibutramine on abdominal fat mass, insulin 
resistance and blood pressure in obese hypertensive patients. Diabetes 
Obes Metab. 2005;7(3):246–253.
88.  Arcaro G, Zamboni M, Rossi L, et al. Body fat distribution predicts 
the degree of endothelial dysfunction in uncomplicated obesity. Int J 
Obes Relat Metab Disord. 1999;23(9):936–942.
89.  Hashimoto M, Akishita M, Eto M, et al. The impairment of flow-
mediated vasodilatation in obese men with visceral fat accumulation. 
Int J Obes Relat Metab Disord. 1998;22(5):477–484.
90.  Vakili BA, Okin PM, Devereux RB. Prognostic implications of left 
ventricular hypertrophy. Am Heart J. 2001;141(3):334–341.
91.  Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic 
implications of echocardiographically determined left ventricular 
mass in the Framingham Heart Study. N Engl J Med. 1990;322(22): 
1561–1566.
92.  Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk 
by reduction of left ventricular mass in hypertension: a meta-analysis. 
Am J Hypertens. 2003;16(11Pt 1):895–899.
93.  de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. 
Relation of obesity and gender to left ventricular hypertrophy in normo-
tensive and hypertensive adults. Hypertension. 1994;23(5):600–606.Vascular Health and Risk Management 2009:5 451
Sibutramine in obesity and related disorders Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  94.  Gottdiener JS, Reda DJ, Materson BJ, et al. Importance of obesity, race 
and age to the cardiac structural and functional effects of hypertension. 
The Department of Veterans Affairs Cooperative Study Group on Anti-
hypertensive Agents. J Am Coll Cardiol. 1994;24(6):1492–1498.
  95.  Wirth A, Scholze J, Sharma AM, Matiba B, Boenner G. Reduced left 
ventricular mass after treatment of obese patients with sibutramine: An 
echocardiographic multicentre study. Diabetes Obes Metab. 2006;8(6): 
674–681.
  96.  Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on 
ventricular dimensions and heart valves in obese patients during weight 
reduction. Am Heart J. 2002;144(3):508–515.
  97.  Malhotra A, White DP. Obstructive sleep apnoea. Lancet. 2002; 
360(9328):237–245.
  98.  Caples SM, Gami AS, Somers VK. Obstructive sleep apnea. Ann 
Intern Med. 2005;142(3):187–197.
  99.  Yee BJ, Phillips CL, Banerjee D, Caterson I, Hedner JA, Grunstein RR. 
The effect of sibutramine-assisted weight loss in men with obstructive 
sleep apnoea. Int J Obes (Lond). 2007;31(1):161–168.
100.  Martinez D, Basile BR. Sibutramine does not worsen sleep apnea 
syndrome: a randomized double-blind placebo-controlled study. Sleep 
Med. 2005;6(5):467–470.
101.  Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12): 
1223–1236.
102.  Florakis D, Diamanti-Kandarakis E, Katsikis I, et al. Effect of 
hypocaloric diet plus sibutramine treatment on hormonal and 
metabolic features in overweight and obese women with polycystic 
ovary syndrome: a randomized, 24-week study. Int J Obes (Lond). 
2008;32(4):692–699.
103.  Lindholm A, Bixo M, Bjorn I, et al. Effect of sibutramine on weight 
reduction in women with polycystic ovary syndrome: a randomized, 
double-blind, placebo-controlled trial. Fertil Steril. 2008;89(5): 
1221–1228.
104.  Sabuncu T, Harma M, Harma M, Nazligul Y, Kilic F. Sibutramine 
has a positive effect on clinical and metabolic parameters in obese 
patients with polycystic ovary syndrome. Fertil Steril. 2003;80(5): 
1199–1204.
105.  Newcomer JW. Antipsychotic medications: metabolic and cardiovas-
cular risk. J Clin Psychiatry. 2007;68(Suppl 4):8–13.
106.  Henderson DC, Copeland PM, Daley TB, et al. A double-blind, 
placebo-controlled trial of sibutramine for olanzapine-associated 
weight gain. Am J Psychiatry. 2005;162(5):954–962.
107.  Baptista T, Uzcategui E, Rangel N, et al. Metformin plus sibutramine 
for olanzapine-associated weight gain and metabolic dysfunction in 
schizophrenia: a 12-week double-blind, placebo-controlled pilot study. 
Psychiatry Res. 2008;159(1–2):250–253.
108.  Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebo-
controlled trial of sibutramine for clozapine-associated weight gain. 
Acta Psychiatr Scand. 2007;115(2):101–105.
109.  Striegel-Moore RH, Franko DL. Should binge eating disorder be 
included in the DSM-V? A critical review of the state of the evidence. 
Annu Rev Clin Psychol. 2008;4:305–324.
110.  Appolinario JC, Godoy-Matos A, Fontenelle LF, et al. An open-label 
trial of sibutramine in obese patients with binge eating disorder. J Clin 
Psychiatry. 2002;63(1):28–30.
111.  Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, double-
blind, placebo-controlled study of sibutramine in the treatment of binge 
eating disorder. Arch Gen Psychiatry. 2003;60(11):1109–1116.
112.  Milano W, Petrella C, Casella A, Capasso A, Carrino S, Milano L. 
Use of sibutramine, an inhibitor of the reuptake of serotonin and 
noradrenaline, in the treatment of binge eating disorder: a placebo-
controlled study. Adv Ther. 2005;22(1):25–31.
113.  Wilfley DE, Crow SJ, Hudson JI, et al. Efficacy of sibutramine for the 
treatment of binge eating disorder: a randomized multicenter placebo-
controlled double-blind study. Am J Psychiatry. 2008;165(1):51–58.
114.  Mersebach H, Klose M, Svendsen OL, Astrup A, Feldt-Rasmussen U. 
Combined dietary and pharmacological weight management in obese 
hypopituitary patients. Obes Res. 2004;12(11):1835–1843.
115.  Mersebach H, Svendsen OL, Astrup A, Feldt-Rasmussen U. Abnormal 
sympathoadrenal activity, but normal energy expenditure in hypopi-
tuitarism. J Clin Endocrinol Metab. 2003;88(12):5689–5695.
116.  Wang Y, Lobstein T. Worldwide trends in childhood overweight and 
obesity. Int J Pediatr Obes. 2006;1(1):11–25.
117.  Ogden CL, Carroll MD, Flegal KM. High body mass index for age 
among US children and adolescents, 2003–2006.  JAMA. 2008;299(20): 
2401–2405.
118.  Tzotzas T, Kapantais E, Tziomalos K, et al. Epidemiological survey 
for the prevalence of overweight and abdominal obesity in Greek 
adolescents. Obesity (Silver Spring). 2008;16(7):1718–1722.
119.  Wang Y, Monteiro C, Popkin BM. Trends of obesity and underweight 
in older children and adolescents in the United States, Brazil, China, 
and Russia. Am J Clin Nutr. 2002;75(6):971–977.
120.  Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation 
of overweight to cardiovascular risk factors among children and 
adolescents: the Bogalusa Heart Study. Pediatrics. 1999;103(6 Pt 1): 
1175–1182.
121.  Duncan GE. Prevalence of diabetes and impaired fasting glucose 
levels among US adolescents: National Health and Nutrition Exami-
nation Survey, 1999–2002. Arch Pediatr Adolesc Med. 2006;160(5): 
523–528.
122.  Daniels SR, Arnett DK, Eckel RH, et al. Overweight in children and 
adolescents: pathophysiology, consequences, prevention, and treat-
ment. Circulation. 2005;111(15):1999–2012.
123.  Krassas GE, Tzotzas D. Do obese children become obese adults: 
childhood predictors of adult disease. Pediatr Endocrinol Rev. 
2004;1(Suppl 3):455–459.
124.  Gunnell DJ, Frankel SJ, Nanchahal K, Peters TJ, Davey Smith G. 
Childhood obesity and adult cardiovascular mortality: a 57-y follow-
up study based on the Boyd Orr cohort. Am J Clin Nutr. 1998;67(6): 
1111–1118.
125.  Engeland A, Bjorge T, Sogaard AJ, Tverdal A. Body mass index in 
adolescence in relation to total mortality: 32-year follow-up of 227,000 
Norwegian boys and girls. Am J Epidemiol. 2003;157(6):517–523.
126.  Berkowitz RI, Fujioka K, Daniels SR, et al. Effects of sibutramine 
treatment in obese adolescents: a randomized trial. Ann Intern Med. 
2006;145(2):81–90.
127.  Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese 
adolescents with sibutramine: a randomized, double-blind, controlled 
study. J Clin Endocrinol Metab. 2005;90(3):1460–1465.
128.  McGovern L, Johnson JN, Paulo R, et al. Treatment of pediatric 
obesity. A systematic review and meta-analysis of randomized trials. 
J Clin Endocrinol Metab. 2008;93(12):4600–4605
129.  Pinkney J, Wilding J, Williams G, MacFarlane I. Hypothalamic 
obesity in humans: what do we know and what can be done? Obes Rev. 
2002;3(1):27–34.
130.  Tzotzas T, Papazisis K, Perros P, Krassas GE. Use of somatostatin 
analogues in obesity. Drugs. 2008;68(14):1963–1973.
131.  Danielsson P, Janson A, Norgren S, Marcus C. Impact sibutramine 
therapy in children with hypothalamic obesity or obesity with aggravat-
ing syndromes. J Clin Endocrinol Metab. 2007;92(11):4101–4106.
132.  Barlow SE. Expert committee recommendations regarding the preven-
tion, assessment, and treatment of child and adolescent overweight and 
obesity: summary report. Pediatrics. 2007;120 Suppl 4:S164–S192.
133.  Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat 
and combination therapy on short-term weight management in obese 
patients. Biomed Pharmacother. 2004;58(10):582–587.
134.  Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U. Comparison 
of efficacy of sibutramine or orlistat versus their combination in obese 
women. Endocr Res. 2004;30(2):159–167.
135.  Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety 
and efficacy of sibutramine, orlistat and metformin in the treatment 
of obesity. Diabetes Obes Metab. 2002;4(1):49–55.
136.  Erondu N, Addy C, Lu K, et al. NPY5R antagonism does not augment 
the weight loss efficacy of orlistat or sibutramine. Obesity (Silver 
Spring). 2007;15(8):2027–2042.Vascular Health and Risk Management 2009:5
Vascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
452
Tziomalos et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
137.  Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS. 
Effects of sibutramine and orlistat on mood in obese and overweight 
subjects: a randomised study. Nutr Metab Cardiovasc Dis. 2008;18(3): 
207–210.
138.  Derosa G, Cicero AF, Murdolo G, et al. Efficacy and safety compara-
tive evaluation of orlistat and sibutramine treatment in hypertensive 
obese patients. Diabetes Obes Metab. 2005;7(1):47–55.
139.  Neovius M, Johansson K, Rossner S. Head-to-head studies evaluating 
efficacy of pharmaco-therapy for obesity: a systematic review and 
meta-analysis. Obes Rev. 2008;9(5):420–427.
140.  Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Com-
parison of metabolic effects of orlistat and sibutramine treatment in 
Type 2 diabetic obese patients. Diabetes Nutr Metab. 2004;17(4): 
222–229.
141.  Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, 
Steinberg CM. Effects of sibutramine plus orlistat in obese women fol-
lowing 1 year of treatment by sibutramine alone: a placebo-controlled 
trial. Obes Res. 2000;8(6):431–437.
142.  Hu G, Barengo NC, Tuomilehto J, Lakka TA, Nissinen A, Jousilahti P. 
Relationship of physical activity and body mass index to the risk of 
hypertension: a prospective study in Finland. Hypertension. 2004; 
43(1):25–30.
143.  Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and 
risk for hypertension in women. Ann Intern Med. 1998;128(2):81–88.
144. [No authors listed]. Effects of weight loss and sodium reduction 
intervention on blood pressure and hypertension incidence in over-
weight people with high-normal blood pressure. The Trials of Hyper-
tension Prevention, phase II. The Trials of Hypertension Prevention 
Collaborative Research Group. Arch Intern Med. 1997;157(6): 
657–667.
145.  Stevens VJ, Obarzanek E, Cook NR, et al; for the Hypertension 
Prevention Research Group. Long-term weight loss and changes in 
blood pressure: results of the Trials of Hypertension Prevention, phase II. 
Ann Intern Med. 2001;134(1):1–11.
146.  Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. 
Influence of Sibutramine on blood pressure: evidence from placebo-
controlled trials. Int J Obes (Lond). 2005;29(5):509–516.
147.  Heusser K, Engeli S, Tank J, et al. Sympathetic vasomotor tone deter-
mines blood pressure response to long-term sibutramine treatment. 
J Clin Endocrinol Metab. 2007;92(4):1560–1563.
148.  Heusser K, Tank J, Diedrich A, et al. Influence of sibutramine treatment 
on sympathetic vasomotor tone in obese subjects. Clin Pharmacol 
Ther. 2006;79(5):500–508.
149.  Birkenfeld AL, Schroeder C, Boschmann M, et al. Paradoxical effect 
of sibutramine on autonomic cardiovascular regulation. Circulation. 
2002;106:2459–2465.
150.  McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of 
sibutramine in obese white and African American patients with 
hypertension: a 1-year, double-blind, placebo-controlled, multicenter 
trial. Arch Intern Med. 2000;160(14):2185–2191.
151.  McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. 
Sibutramine is safe and effective for weight loss in obese patients 
whose hypertension is well controlled with angiotensin-converting 
enzyme inhibitors. J Hum Hypertens. 2002;16(1):5–11.
152.  Sramek JJ, Leibowitz MT, Weinstein SP, et al. Efficacy and safety of 
sibutramine for weight loss in obese patients with hypertension well 
controlled by beta-adrenergic blocking agents: a placebo-controlled, 
double-blind, randomised trial. J Hum Hypertens. 2002;16(1):13–19.
153.  Scholze J, Grimm E, Herrmann D, Unger T, Kintscher U. Optimal 
treatment of obesity-related hypertension: the Hypertension-Obesity-
Sibutramine (HOS) study. Circulation. 2007;115(15):1991–1998.
154.  Horvath K, Jeitler K, Siering U, et al. Long-term effects of weight-
reducing interventions in hypertensive patients: systematic review and 
meta-analysis. Arch Intern Med. 2008;168(6):571–580.
155.  Cook S, Togni M, Schaub MC, Wenaweser P, Hess OM. High heart rate: 
a cardiovascular risk factor? Eur Heart J. 2006;27(20):2387–2393.
156.  Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, 
and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J. 
1991;121(1 Pt 1):172–177.
157.  Ernest D, Gershenzon A, Corallo CE, Nagappan R. Sibutramine-
associated QT interval prolongation and cardiac arrest.  Ann Phar­
macother. 2008;42(10):1514–1517.
158.  Harrison-Woolrych M, Clark DW, Hill GR, Rees MI, Skinner JR. QT 
interval prolongation associated with sibutramine treatment. Br J Clin 
Pharmacol. 2006;61(4):464–469.
159.  Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence 
with orlistat and sibutramine in a population-based cohort. Int J Obes 
(Lond). 2007;31(10):1567–1570.
160.  Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and 
sibutramine: results of prescription-event monitoring studies in England. 
Obesity (Silver Spring). 2007;15(11):2712–2722.
161.  Hill GR, Ashton J, Harrison-Woolrych M. Sibutramine usage in New 
Zealand: an analysis of prescription data by the Intensive Medicines 
Monitoring Programme. Pharmacoepidemiol. Drug Saf. 2007;16(11): 
1217–1226.
162.  James WP. The SCOUT study: risk-benefit profile of sibutramine in 
overweight high-risk cardiovascular patients. Eur Heart J Supplements. 
2005;7(suppl L):L44–L48.
163.  Torp-Pedersen C, Caterson I, Coutinho W, et al; SCOUT Investigators. 
Cardiovascular responses to weight management and sibutramine in 
high-risk subjects: an analysis from the SCOUT trial. Eur Heart J. 
2007;28(23):2915–2923.